Search

Your search keyword '"Nevill, Thomas"' showing total 11 results
Start Over Author "Nevill, Thomas" Journal leukemia & lymphoma
11 results on '"Nevill, Thomas"'

1. The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry

Author

Buckstein, Rena, primary, Chodirker, Lisa, additional, Yee, Karen W.L., additional, Geddes, Michelle, additional, Leitch, Heather A., additional, Christou, Grace, additional, Banerji, Versha, additional, Leber, Brian, additional, Khalaf, Dina, additional, St-Hilaire, Eve, additional, Finn, Nicholas, additional, Nevill, Thomas, additional, Keating, Mary-Margaret, additional, Storring, John, additional, Parmentier, Anne, additional, Thambipillai, Aksharh, additional, Tang, Derek, additional, Westcott, Christopher, additional, Cameron, Chris, additional, and Spin, Paul, additional

Published
2023
Full Text
View/download PDF

2. A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry

Author

Buckstein, Rena, primary, Chodirker, Lisa, additional, Mozessohn, Lee, additional, Yee, Karen W.L, additional, Geddes, Michelle, additional, Zhu, Nancy, additional, Shamy, April, additional, Leitch, Heather A., additional, Christou, Grace, additional, Banerji, Versha, additional, Brian, Leber, additional, Khalaf, Dina, additional, St-Hilaire, Eve, additional, Finn, Nicholas, additional, Nevill, Thomas, additional, Keating, Mary-Margaret, additional, Storring, John, additional, Delage, Robert, additional, Parmentier, Anne, additional, Thambipillai, Aksharh, additional, Siddiqui, Mohammed, additional, Westcott, Christopher, additional, Cameron, Chris, additional, Mamedov, Alexandre, additional, Spin, Paul, additional, and Tang, Derek, additional

Published
2022
Full Text
View/download PDF

3. Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia

Author

Kliman, David, primary, Barnett, Michael, additional, Broady, Raewyn, additional, Forrest, Donna, additional, Gerrie, Alina, additional, Hogge, Donna, additional, Nantel, Stephen, additional, Narayanan, Sujaatha, additional, Nevill, Thomas, additional, Power, Maryse, additional, Sanford, David, additional, Song, Kevin, additional, Sutherland, Heather, additional, Toze, Cynthia, additional, and Abou Mourad, Yasser, additional

Published
2016
Full Text
View/download PDF

4. Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia.

Author

Kliman, David, Barnett, Michael, Broady, Raewyn, Forrest, Donna, Gerrie, Alina, Hogge, Donna, Nantel, Stephen, Narayanan, Sujaatha, Nevill, Thomas, Power, Maryse, Sanford, David, Song, Kevin, Sutherland, Heather, Toze, Cynthia, and Abou Mourad, Yasser

Subjects
PHYSIOLOGICAL effects of chemotherapy, MEDICAL standards, LYMPHOBLASTIC leukemia treatment, LYMPHOCYTIC leukemia, HEALTH of patients, LEUKEMIA treatment
Abstract

We investigated the utility of a pediatric-inspired protocol in adults aged 18–40 years with standard-riskBCR-ABLnegative acute lymphoblastic leukemia (ALL). Retrospective outcomes of 25 patients treated with a pediatric protocol between 2008 and 2014 were compared with 22 similarly aged patients treated with an adult protocol between 2003 and 2008. Twenty-five (100%) and 19 (86%) patients achieved complete remission, respectively. At median follow-up of 36.8 months, 3-year event-free survival was increased in patients on the pediatric protocol at 80% versus 45% (p = .019). There was a trend toward improved overall survival at 80% versus 59% (p = .12). Treatment-related toxicity was not increased despite the increased treatment intensity. Patients withBCRand/orABLcopy number variation demonstrated comparatively poorer outcomes in both cohorts. In our experience with this cohort of patients, pediatric-based protocols are safe and effective, justifying their use in younger adults with ALL. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

5. Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy

Author

Tantiworawit, Adisak, primary, Power, Maryse M., additional, Barnett, Michael J., additional, Hogge, Donna E., additional, Nantel, Stephen H., additional, Nevill, Thomas J., additional, Shepherd, John D., additional, Song, Kevin W., additional, Sutherland, Heather J., additional, Toze, Cynthia L., additional, Abou-Mourad, Yasser R., additional, Narayanan, Sujaatha, additional, Broady, Raewyn C., additional, and Forrest, Donna L., additional

Published
2012
Full Text
View/download PDF

6. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)

Author

Venner, Christopher P., primary, Connors, Joseph M., additional, Sutherland, Heather J., additional, Shepherd, John D., additional, Hamata, Linda, additional, Mourad, Yasser Abou, additional, Barnett, Michael J., additional, Broady, Raewyn, additional, Forrest, Donna L., additional, Hogge, Donna E., additional, Nantel, Stephen H., additional, Narayanan, Sujaatha, additional, Nevill, Thomas J., additional, Nitta, Janet, additional, Power, Maryse M., additional, Toze, Cynthia L., additional, Smith, Clayton A., additional, and Song, Kevin W., additional

Published
2010
Full Text
View/download PDF

7. Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission

Author

Song, Kevin W, primary, Mollee, Peter N, additional, Hogge, Donna E, additional, Gupta, Vikas, additional, Barnett, Michael J, additional, Forrest, Donna L, additional, Lavoie, Julye C, additional, Nevill, Thomas J, additional, Nantel, Stephen H, additional, Shepherd, John D, additional, Smith, Clay A, additional, Sutherland, Heather J, additional, Toze, Cynthia L, additional, Crump, Michael, additional, and Keating, Armand, additional

Published
2005
Full Text
View/download PDF

10. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).

Author

Venner, Christopher P., Connors, Joseph M., Sutherland, Heather J., Shepherd, John D., Hamata, Linda, Mourad, Yasser Abou, Barnett, Michael J., Broady, Raewyn, Forrest, Donna L., Hogge, Donna E., Nantel, Stephen H., Narayanan, Sujaatha, Nevill, Thomas J., Nitta, Janet, Power, Maryse M., Toze, Cynthia L., Smith, Clayton A., and Song, Kevin W.

Subjects
MULTIPLE myeloma, STEM cell transplantation, THALIDOMIDE, MEDICAL protocols, DRUG therapy, COMBINATION drug therapy, PATIENTS
Abstract

The treatment of multiple myeloma (MM) has changed with the advent of thalidomide, bortezomib, and lenalidomide, the so-called novel agents (NAs). Given the complexity of MM therapy in the NA era we pursued a population based study to assess for improvements in survival as well as to characterize the relevance of early relapse (within 12 months) and the International Staging System in this clinical setting. We reviewed our experience with 460 patients with MM treated with autologous stem cell transplant (ASCT) between 1988 and 2008, of whom 306 had relapsed. The cohort was divided into two groups based upon relapse pre-2004 and relapse during/after 2004 (2004+), which correlated to availability of bortezomib and lenalidomide. Improvements in both overall survival (OS) (median 32.0 months vs. 71.8 months; p < 0.001) and post-relapse survival (PRS) (median 15.2 months vs. 42.8 months; p < 0.001) correlated with the NA era. Exposure to NAs conferred a better PRS (median 35.7 months vs. 9.1 months; p < 0.001). Although all patients had improvements in survival, those who relapsed late continued to do better. Lastly, in the NA era, the ISS remains an important prognostic tool in relapse, but only in the late relapsing cohort. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

11. Improvement in quality of life in MDS patients who become transfusion independent after treatment.

Author

Wan, Bo A., Alibhai, Shabbir M. H., Chodirker, Lisa, Mozessohn, Lee, Geddes, Michelle, Zhu, Nancy, Trottier, Amy M., St-Hilaire, Eve, Finn, Nicholas, Leber, Brian, Khalaf, Dina, Christou, Grace, Sabloff, Mitchell, Leitch, Heather A., Shamy, April, Yee, Karen W. L., Storring, John, Nevill, Thomas J., Houston, Brett L., and Elemary, Mohamed

Subjects
*MYELODYSPLASTIC syndromes, *SOCIAL skills, *QUALITY of life, *ANEMIA, *SYNDROMES
Abstract

AbstractMyelodysplastic syndromes (MDSs) treatment focuses on improving quality of life (QOL), affected by anemia and transfusion dependence (TD). Using the MDS-CAN registry, we studied how changes in transfusion status – TD to transfusion independence (TI) (group A), or vice versa (group B), and maintaining TD (group C) or TI (group D) – affected OS and QOL in 1120 MDS patients. Analysis showed superior OS for those remaining TI, poorer for those remaining TD, and intermediate for those with changes. Among 656 treated patients, group A (n = 54) showed improved QOL, with trends toward improved physical and social function scores. Group B (n = 151) experienced declines in global QOL measures after switching to TD, particularly in fatigue and physical, role, and social functioning. Group C had notable fatigue worsening, while group D showed milder declines across multiple QOL aspects. Achieving TI in MDS correlates with improved QOL, whereas reverting to TD more significantly worsens overall QOL and function scores. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results